B. Riley initiated coverage on Neuronetics with a Buy rating. The firm set a $5.00 price target. This valuation suggests significant upside from the $3.01 closing price.
Analyst Madison El-Saadi expects the late-2024 Greenbrook acquisition to transform the business. A management reset is scheduled for 2026 to further the transition.
The integration shifts Neuronetics toward a scalable interventional psychiatry platform. Greenbrook is projected to deliver mid-teens organic growth. The firm is also positioned to capitalize on a potential industry shift toward psychedelic-driven treatments. Rising commercial and payer acceptance provides additional momentum for the strategy.